Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2042846 | 0.88 | POLB (0.47) | SMN1; SMN2GAAL3MBTL1HDAC1HDAC2 | |
| SCHEMBL6300484 | 0.86 | POLB (0.43) | SMN1; SMN2MEN1GAAKMT2AHDAC1 | |
| SCHEMBL7503707 | 0.85 | POLB (0.48) | SMN1; SMN2HSD17B10ALDH1A1MAPK1MEN1 | |
| SCHEMBL26574069 | 0.85 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1MAPK1MEN1GAA | |
| SCHEMBL8486574 | 0.84 | POLB (0.48) | SMN1; SMN2MEN1GAAKMT2AHDAC1 | |
| SCHEMBL24341715 | 0.84 | CNR1 (0.38) | SMN1; SMN2HSD17B10ALDH1A1MAPK1MEN1 | |
| SCHEMBL6563271 | 0.84 | POLB (0.46) | SMN1; SMN2MEN1GAAKMT2AHDAC1 | |
| SCHEMBL20025128 | 0.84 | POLB (0.47) | SMN1; SMN2MEN1GAAKMT2AHDAC1 | |
| SCHEMBL17282042 | 0.83 | POLB (0.37) | SMN1; SMN2HSD17B10ALDH1A1MAPK1HDAC1 | |
| SCHEMBL6302650 | 0.82 | POLB (0.43) | SMN1; SMN2MEN1GAAKMT2AHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2512523-A1 | LABELLED INTEGRIN BINDERS | GE Healthcare UK Limited (GB) | 2012-10-24 | — | — | EP | disclosed |
| US-20120244074-A1 | LABELLED INTEGRIN BINDERS | GE HEALTHCARE LIMITED (GB) | 2012-09-27 | — | — | US | disclosed |
| WO-2011073340-A1 | LABELLED INTEGRIN BINDERS | GE HEALTHCARE LIMITED (GB) | 2011-06-23 | — | — | WO | disclosed |
| US-7119098-B2 | Heteroarylakanoic acids as intergrin receptor antagonists | PHARMACIA CORPORATION (US) | 2006-10-10 | — | — | US | disclosed |
| US-6933304-B2 | Heteroarylalkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION (US) | 2005-08-23 | — | — | US | disclosed |
| US-20040092497-A1 | Heteroarylakanoic acids as intergrin receptor antagonists | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| EP-1289983-A2 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | Pharmacia Corporation (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020133023-A1 | Heteroarylalkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION | 2002-09-19 | — | — | US | disclosed |
| WO-2001096334-A2 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133023-A1 | Heteroarylalkanoic acids as integrin receptor antagonists | ITGA5, ITGA2B, ITGAV | SMN1; SMN2 3712/4885HSD17B10 1734/4885ALDH1A1 669/4885 |
| US-20040092497-A1 | Heteroarylakanoic acids as intergrin receptor antagonists | ITGA5, ITGB7, ITGA2B | SMN1; SMN2 4329/4885HSD17B10 1402/4885ALDH1A1 834/4885 |
| US-20120244074-A1 | LABELLED INTEGRIN BINDERS | ITGAV, ITGB6, ITGA2B | SMN1; SMN2 2504/4885HSD17B10 4672/4885ALDH1A1 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.